drugset
drugset / Trial / NCT04162821

Study on Pharmacokinetics of Hydronidone

NCT04162821 ↗

Phase 1 Completed 48 enrolled Beijing Continent Pharmaceutical Co, Ltd.
RandomizedParallel-groupOpen-labelBasic science

Summary

To evaluate the pharmacokinetic characteristics of hydronidone capsules (specification: 30 mg/ pill) in healthy subjects And the effect of feeding on pharmacokinetics to provide evidence for phase II/III clinical trial protocols.

Timeline

Start
2019-10-30
Primary completion
2019-11-27
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydronidone Small molecule 60 mg —
Subject Hydronidone Small molecule 90 mg —
Subject Hydronidone Small molecule 120 mg —

Indications

No indication recorded.